Oxford Biomedica plc (OXB.L) LSE

632.30

+0.3(+0.05%)

Updated at April 23 03:14PM

Currency In GBp

Key Executives

Name	Title	Pay	Year Born
Frank Mathias	Chief Executive Officer & Director	1.11M	1962
Lucinda Crabtree	CFO & Director	512,425	1979
Kyriacos Mitrophanous	Chief Information Officer	0	N/A
Sebastien Ribault	Chief Business Officer	0	N/A
Mark Caswell	Site Head of UK Operations	0	N/A
Thierry Cournez	Chief Operating Officer	0	N/A
Kati Hudson	Head of Intellectual Property and Contracts	0	N/A
Lisa Doman	Chief People Officer	0	N/A
Natalie Louise Walter	Chief Legal Officer & Company Secretary	0	1973
Sophia Bolhassan	Head of Investor Relations	0	N/A

Name

Title

Pay

Year Born

Frank Mathias

Chief Executive Officer & Director

1.11M

1962

Lucinda Crabtree

CFO & Director

512,425

1979

Kyriacos Mitrophanous

Chief Information Officer

N/A

Sebastien Ribault

Chief Business Officer

N/A

Mark Caswell

Site Head of UK Operations

N/A

Thierry Cournez

Chief Operating Officer

N/A

Kati Hudson

Head of Intellectual Property and Contracts

N/A

Lisa Doman

Chief People Officer

N/A

Natalie Louise Walter

Chief Legal Officer & Company Secretary

1973

Sophia Bolhassan

Head of Investor Relations

N/A

Description

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.